QNCX
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
Quince Therapeutics Inc (QNCX) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.
Quantitative Factor Evaluation • Updated
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | C+ (2.5) | D (1.3) | D+ (1.6) | A- (4.1) | A+ (5.0) | B- (2.9) |
| 2026-11-07 | C+ (2.5) | D (1.3) | D+ (1.6) | B+ (3.7) | A+ (5.0) | C+ (2.8) |
| 2026-10-31 | C+ (2.5) | D (1.3) | D+ (1.7) | A (4.3) | A+ (5.0) | B- (3.0) |
| 2026-10-24 | C+ (2.5) | D (1.3) | D+ (1.6) | A (4.5) | A+ (5.0) | B- (3.0) |
Showing the last month only. Subscribe for the full factor score history.
For more — Subscribe